208 related articles for article (PubMed ID: 31993719)
1. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
Yoshida T; Kinoshita H; Taniguchi H; Yanishi M; Sugi M; Matsuda T
Osteoporos Int; 2020 Jul; 31(7):1251-1259. PubMed ID: 31993719
[TBL] [Abstract][Full Text] [Related]
2. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
3. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Joseph JS; Lam V; Patel MI
Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
5. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
[TBL] [Abstract][Full Text] [Related]
6. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of denosumab in men with prostate cancer.
Sølling AS; Harsløf T; Brockstedt HK; Langdahl B
Osteoporos Int; 2023 Feb; 34(2):291-297. PubMed ID: 36402867
[TBL] [Abstract][Full Text] [Related]
8. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
9. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
10. Initiation of Monthly Minodronate Therapy at an Early Stage After Hip Fracture.
Ohishi T; Fujita T; Suzuki D; Nishida T; Okabayashi R; Yamamoto K; Ushirozako H; Banno T; Matsuyama Y
J Clin Densitom; 2016; 19(3):352-8. PubMed ID: 27067298
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy.
Ziaran S; Goncalves FM; Breza JS
Endocr Regul; 2011 Oct; 45(4):199-204. PubMed ID: 22073949
[TBL] [Abstract][Full Text] [Related]
13. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
14. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
16. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
Okazaki R; Hagino H; Ito M; Sone T; Nakamura T; Mizunuma H; Fukunaga M; Shiraki M; Nishizawa Y; Ohashi Y; Matsumoto T
Osteoporos Int; 2012 Jun; 23(6):1737-45. PubMed ID: 21932114
[TBL] [Abstract][Full Text] [Related]
19. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
